Latest California Healthline Stories
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
A hearing before a House Oversight and Reform Committee panel on how to address the crisis of respiratory injuries related to vaping turned surprisingly partisan.
The House speaker announced her plan for lowering drug prices, which includes negotiations between drugmakers and federal health officials.
Tennessee wants to convert its Medicaid program to a block grant. But is its plan legal? Meanwhile, Congress continues to struggle with legislation to rein in prescription drug prices and surprise medical bills. This week, Anna Edney of Bloomberg News, Jennifer Haberkorn of the Los Angeles Times and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss these issues and more. Rovner also interviews Dr. Marty Makary, author of the new book “The Price We Pay” about why health care costs so much.
Barbara Van Rooyan lost her son to the drug 15 years ago and has fought ceaselessly since then to hold Purdue Pharma accountable for its role in the opioid crisis.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Nearly 2 million more Americans were uninsured in 2018 than in the previous year, according to the Census Bureau’s annual report. Plus, the Trump administration announced plans to ban flavored vape liquids, and Congress is back and working to address high prescription drug prices and “surprise” medical bills. This week, Joanne Kenen of Politico, Tami Luhby of CNN and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
In the first six months of this year, pharmaceutical firms and their trade groups donated almost $4 million to the campaigns of a variety of senators and House members.
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
So far this year, 33 states have enacted more than 50 measures to address drug prices, affordability and access. Congress is eyeing the efforts to see what works.